5月19日至5月25日，券商给予上市公司目标价共223次，按最新收盘价计算，目标价涨幅排名居前的公 司有凯因科技、亚信安全、今世缘，目标价涨幅分别为68.49%、67.84%、65.93%，分别属于生物制 品、软件开发、白酒行业。 | | | | 5月19日全5月25日目标价获幅排名 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 证券代码 证券名称 | | 机构 | 最新评级 | 废局日标0 | | | 行业 | | 688687 | 凯因科技 | 华泰金融控股(香港) | 头人 | 44. 97 | 26. 69 | 68. 49 | 生物制品 | | 688225 | 亚信安全 | 国泰海通证券 | 增持 | 33. 40 | 19. 90 | 67.84 | 软件开发 | | 603369 | 今世缘 | 华创证券 | 强推 | 75.00 | 45. 20 | 65. 93 | 日酒 | | 600519 | 贵州茅台 | 华创证券 | 强推 | 2600. 00 | 1572. 60 | 65. 33 | 日酒 | | 6 ...

Core Viewpoint - The stock price of Giant Bio (HK02367) experienced a significant decline following allegations of product fraud related to its brand, Kefu Mei, which led to a public statement denying the accusations and asserting compliance with regulatory standards [9][10]. Group 1: Company Performance - As of May 26, Giant Bio's stock opened with a drop exceeding 8%, later narrowing to a decline of 3.52% [1]. - The company's market capitalization is approximately 80 billion HKD [11]. - Kefu Mei, a brand under Giant Bio, reported sales revenue exceeding 4.5 billion CNY in 2024, reflecting a year-on-year growth of 62.9% [10]. Group 2: Industry Context - The A-share market saw a collective decline in stocks related to recombinant protein, with notable drops in companies such as Ruizhi Pharmaceutical and Sanofi Guojian, each falling nearly 6% [2]. - The market reaction indicates a broader concern regarding the credibility of companies in the recombinant protein sector following the allegations against Giant Bio [2].

Group 1 - The overall quality of companies waiting for listing on the Beijing Stock Exchange (BSE) is high, with an average net profit of 89.67 million yuan for 94 companies, significantly higher than the average of 42.11 million yuan for 266 listed companies [3][15][17] - The average subscription rate for companies that raised over 200 million yuan is 0.14%, compared to 0.06% for those that raised less than 200 million yuan, indicating a correlation between fundraising size and subscription success [14][21] - The expected new stock subscription yield for 2025 is estimated to be between 4.8% and 10.80%, based on various assumptions regarding market conditions and investor participation [20][21] Group 2 - The BSE 50 index experienced a decline of 3.68% this week, closing at 1370.04 points, following a previous high of 1500 points, indicating potential volatility in the market [4][25][29] - The overall price-to-earnings (PE) ratio for BSE A-shares has decreased to 48.45X, with 53.79% of companies having a PE ratio exceeding 45X, suggesting a high valuation environment [22][26][27] - The five major industries on the BSE, including high-end equipment and information technology, have varying PE ratios, with information technology at 92.82X, indicating sector-specific valuation disparities [32][34] Group 3 - The average first-day price increase for newly listed companies from January 1, 2024, to May 23, 2025, is 303.91%, with the highest recorded increase being 731.41% for Tongguan Mining [44] - The IPO review process is active, with two companies awaiting approval and two newly accepted for review, reflecting ongoing market activity [5][42] - The report highlights the importance of focusing on companies with stable performance and reasonable valuations, particularly those classified as "little giants" in their respective sectors [39][41]

截至2025年5月23日收盘，上海莱士（002252）报收于6.8元，较上周的6.76元上涨0.59%。本周，上海 莱士5月22日盘中最高价报6.93元。5月19日盘中最低价报6.73元。上海莱士当前最新总市值451.38亿 元，在生物制品板块市值排名3/50，在两市A股市值排名290/5148。 公司公告汇总 关于控股股东增持股份计划的公告。证券代码：002252 证券简称：上海莱士 公告编号：2025-043。控 股股东海盈康（青岛）医疗科技有限公司基于对公司未来发展的信心和长期投资价值的认同，计划自本 公告披露之日起6个月内，通过深圳证券交易所交易系统以集中竞价交易方式增持公司股份，增持总金 额不低于人民币25,000万元，且不超过人民币50,000万元，不设置价格区间。本次增持计划资金来源为 自有资金及股份增持专项贷款，其中专项贷款资金占比不超过90%，中国银行股份有限公司青岛市分行 为海盈康提供不超过4.5亿元的股票增持专项贷款支持。海盈康承诺在增持期间及法定期限内不减持公 司股份，不进行内幕交易、短线交易等行为。本次增持计划不触及要约收购，不会导致公司股权分布不 符合上市条件，不会导致公司控制权发 ...

Group 1 - The core viewpoint of the news highlights the strong performance and growing popularity of the Hong Kong Stock Connect Innovative Drug ETF (工银159217), which has seen significant trading activity and net inflows since its launch [1][2] - As of May 22, the ETF recorded a trading volume of 4.59 billion yuan and a turnover rate of 12.46%, indicating active trading [1] - The ETF has achieved a new high in scale, reaching 36.74 billion yuan, with an average daily trading volume of 2.12 billion yuan since its listing on April 3 [1] Group 2 - The ETF closely tracks the National Index of Hong Kong Stock Connect Innovative Drugs, which reflects the operational characteristics of listed companies in the innovative drug sector [1] - The price-to-earnings ratio (PE-TTM) of the index is 26.97, placing it in the lowest 3.22% of its historical range over the past decade, indicating a low valuation [1] - The index's constituent stocks are heavily concentrated in the biopharmaceutical and chemical pharmaceutical sectors, which together account for over 90% of the index [1] Group 3 - The management fee and custody fee for the ETF are 0.4% and 0.07%, respectively, making it the lowest among similar products tracking the National Index [2] - The ETF allows for T+0 trading, enhancing liquidity for investors [2] - Recent developments in the Hong Kong market, including the listing of leading innovative drug companies, have attracted investor attention [2] Group 4 - The report from Guangfa Securities emphasizes the importance of focusing on the Hong Kong innovative drug sector, highlighting the global competitive advantages of Chinese innovative drugs [2] - The rise of the NewCo model has addressed challenges such as financing difficulties and high research and development risks for original drug companies [2] - Positive policy signals have emerged in the second half of 2023, including rule optimizations and increased support for innovative drugs, contributing to the growth of leading Hong Kong innovative drug companies [2]

Market Overview - On May 22, major market indices collectively retreated, with a total trading volume of 1.14 trillion yuan, a decrease of 74.7 billion yuan compared to the previous day [1] - The number of stocks that rose was less than 900, while nearly 4,500 stocks declined, with 51 stocks hitting the daily limit up and 18 stocks hitting the daily limit down [1] - Industry sectors experienced widespread declines, with beauty care, social services, and basic chemicals dropping over 1.5%, while only banking, media, and household appliances saw gains [1] Stockholder Changes - A total of 365 stocks reported changes in shareholder numbers as of May 20, with 170 stocks seeing a decrease in shareholder accounts compared to May 10 [2] - The stock with the largest decline in shareholder accounts was Shanshui Bide, which saw a 33.18% drop to 4,909 accounts [2] - Ji Qi Co., Ltd. also reported a significant decrease of 15.50% in shareholder accounts, totaling 17,413 [2] Institutional Trading - On May 22, 10 stocks saw net purchases from institutions, with Tianqi Mould and Aerospace Nanhu receiving over 50 million yuan in net buying [3] - The stock San Sheng Guo Jian faced the largest net selling from institutions, amounting to 151 million yuan, following a 100% increase in price over four consecutive days of hitting the daily limit up [3][4] - The institutional trading data indicates a trend of increasing net selling for San Sheng Guo Jian over three consecutive days [3] Northbound Capital Flow - On May 22, seven stocks experienced net buying from northbound funds, with San Sheng Guo Jian leading at 35.03 million yuan [5] - The stock Lianyun Port saw the highest net selling from northbound funds, totaling 51.66 million yuan [5] Important Announcements - Chao Da Equipment was selected for the 2025 Jiangsu Province Advanced Intelligent Factory list for its smart collaborative manufacturing project [6] - Bo Rui Pharmaceutical received a drug registration certificate for Iopamidol injection from the National Medical Products Administration [6] - Chengdu Xian Dao's shareholder plans to increase its stake in the company by 25 to 50 million yuan without a set price range [6] - Xinhua Insurance signed a contract to establish a private equity fund with a total scale of 20 billion yuan, contributing 10 billion yuan [6] - Zhongnan Media's subsidiary signed a government procurement contract worth 1.009 billion yuan, positively impacting the company's operations in 2025 [6]

Group 1 - The core viewpoint of the article indicates that the company has a rolling price-to-earnings (P/E) ratio of 48.81, which is significantly higher than the industry average [1] - The company's stock has increased by over 100% since May 19, 2025, suggesting potential irrational speculation and a possible correction [1] - The company and its controlling shareholders do not have any undisclosed significant matters regarding the company, and its daily operations remain normal without major changes [1] Group 2 - There have been no significant adjustments in the industry policies affecting the company [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has entered into a significant agreement with Pfizer regarding the global development, production, and commercialization rights for its innovative PD-1/VEGF bispecific antibody SSGJ-707, which includes an upfront payment of $1.25 billion and potential milestone payments of up to $4.8 billion [6] - The company maintains its profit forecast, expecting net profits of 2.328 billion, 2.612 billion, and 2.938 billion CNY for the years 2025, 2026, and 2027 respectively, with corresponding EPS of 0.97, 1.09, and 1.23 CNY per share [6] - The current stock price corresponds to a PE ratio of 9.3, 8.3, and 7.4 for the years 2025, 2026, and 2027 respectively, indicating a favorable valuation [6] Financial Summary and Valuation Indicators - The company's revenue is projected to grow from 7.836 billion CNY in 2023 to 10.078 billion CNY in 2025, reflecting a year-over-year growth rate of 14.1% and 10.7% respectively [9] - Net profit is expected to increase from 1.549 billion CNY in 2023 to 2.328 billion CNY in 2025, with a year-over-year growth of (19.1%) in 2023, followed by 34.9% in 2024 and 11.4% in 2025 [9] - The gross margin is projected to remain stable at around 84.2% from 2025 to 2027, while the net margin is expected to improve slightly from 26.6% in 2025 to 26.8% in 2027 [9] - The company’s ROE is forecasted to increase from 0.8% in 2025 to 1.1% in 2027 [9] Pipeline and Product Development - The company’s core product SSGJ-707 has shown promising results in clinical trials for NSCLC, achieving excellent ORR and DCR, and has received breakthrough therapy designation from the National Medical Products Administration [7] - The company is advancing multiple clinical studies for SSGJ-707, including a Phase III trial for NSCLC and ongoing research for colorectal cancer and gynecological tumors [7] - The company’s existing products, including Tebentafusp and others, are expected to contribute positively to cash flow, with successful negotiations for new indications enhancing growth potential [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has entered into a significant agreement with Pfizer regarding the global development, production, and commercialization rights for its innovative PD-1/VEGF bispecific antibody SSGJ-707, which highlights the company's innovative capabilities and potential for value realization [6] - The company is expected to maintain its profit forecasts, with projected net profits of 2.328 billion, 2.612 billion, and 2.938 billion yuan for the years 2025 to 2027, respectively, and corresponding EPS of 0.97, 1.09, and 1.23 yuan per share [6] - The current stock price corresponds to a PE ratio of 9.3, 8.3, and 7.4 for the years 2025 to 2027, indicating a favorable valuation [6] Financial Summary and Valuation Indicators - Revenue for 2023 was 7.836 billion yuan, with projections of 9.108 billion yuan for 2024 and 10.078 billion yuan for 2025, reflecting a year-over-year growth of 14.1%, 16.2%, and 10.7% respectively [9] - Net profit for 2023 was 1.549 billion yuan, with projections of 2.090 billion yuan for 2024 and 2.328 billion yuan for 2025, showing a year-over-year growth of (19.1)%, 34.9%, and 11.4% respectively [9] - The gross margin is expected to remain stable at around 84.2% from 2025 to 2027, while the net margin is projected to increase from 26.6% in 2025 to 26.8% in 2027 [9] - The company’s ROE is projected to improve from 0.8% in 2025 to 1.1% in 2027 [9]

Core Viewpoint - High-quality development is an essential requirement for Chinese-style modernization, as emphasized by President Xi Jinping during his recent visit to Henan, inspiring local officials and citizens to pursue this goal with determination and enthusiasm [3]. Group 1: Economic Development and Trade - Henan, as an inland province, views openness as a vital source of economic growth, with plans to enhance high-level foreign trade and deepen integration into the Belt and Road Initiative [4]. - The China-Europe Railway Express from Henan has significantly expanded from one train per month to ten per day, establishing a logistics network that covers over 40 countries and 140 cities, with a total of 14,400 trains operated [5]. - Zhengzhou Airport has opened 58 cargo routes, serving 31 countries and 63 cities, with international cargo volume reaching 220,000 tons, a 47.8% increase year-on-year [6]. Group 2: Financial Support and Stability - The provincial government is committed to enhancing the financial support for the real economy, particularly for private and small enterprises, ensuring that credit reaches grassroots levels efficiently [9]. - The government aims to stabilize the real estate market by implementing policies that reduce housing costs and promote project construction and delivery [10]. Group 3: Industrial and Technological Innovation - The focus is on strengthening the manufacturing sector and fostering a modern industrial system through technological innovation and collaboration between industry and research [11]. - Companies like Henan Jindan Lactide Technology Co., Ltd. are committed to advancing high-end, intelligent, and green production processes in the bioplastics sector [12][13]. - The province is prioritizing the integration of technology and industry to enhance productivity and competitiveness, with initiatives aimed at overcoming key technological challenges [14][15][16].